renzapride
Sign in to saveAlso known as BRL 24924, BRL-24924
Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors.
Research
161 papers- Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome.Expert opinion on investigational drugs · 2008
- Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients.Archives of medical science : AMS · 2014
- The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.The Journal of international medical research · 2007
- Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.Drugs in R&D · 2008
- Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study.Alimentary pharmacology & therapeutics · 2010
via PubMed
~3 min read
Encyclopedic overview
3 sectionsContents
- Clinical trials
- See also
- References
Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors.
Renzapride was being developed by Alizyme plc of the United Kingdom. In May 2016, EndoLogic LLC, a US-based pharmaceutical and medical device company, acquired the US and worldwide patent rights to Renzapride.
Excerpted from Wikipedia’s “renzapride” article, available under the CC BY-SA 4.0 licence.